Ask HopeStage to review this study with me
Leave your email and HopeStage can help you better understand this study.
Study reference: NCT07409298. HopeStage can help you review the study, but cannot decide medical eligibility.
Enrolling By InvitationNCT07409298
Impact of an Artificial Intelligence-Based Management Model on Psychological and Behavioral Outcomes in Breast Cancer Patients Undergoing Home CDK4/6 Inhibitor Therapy
This study is enrolling by invitation in China. It focuses on CDK4/6 Inhibitors; Depression Anxiety Disorder; Breast Cancer.
AnxietyOtherFrom 18 Years to 80 Years
Key information made simple
This study is looking at whether The "Zhiliao Doctor" AI management platform can help people with CDK4/6 Inhibitors, Depression anxiety, or Breast Cancer. Participants receive a study treatment and complete follow-up visits and assessments. Taking part may give some people access to The "Zhiliao Doctor" AI management platform, but direct benefit is not guaranteed.
Your next step
The official record suggests in-person participation through a hospital, with sites including Tianjin Medical University Cancer Institute & Hospital. Participation appears to involve a study treatment together with follow-up visits and routine safety or progress checks. The main fit is usually matching the main diagnosis, while common reasons not to take part include pregnancy or breastfeeding. The official record does not list a formal phase, which usually means this is focused more on feasibility, delivery, or support than a standard drug-development stage.
Questions to ask before joining
- What are the exact eligibility criteria, and what could exclude someone?
- How many visits, assessments, or follow-ups are expected, and over what period?
- What risks, side effects, practical burdens, or alternatives should be understood first?
- Who should be contacted to confirm locations, timing, compensation, and next steps?
Things to check before joining
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Sponsor type
- University
- Main activity
- behavioral or lifestyle intervention
- Intervention
- Not available
- Time commitment
- long follow-up or multiple visits
- Study phase
- Not available
- Enrollment
- Not available
- Recruitment status
- Enrolling By Invitation
- Source
- Official registry link
Key study information
- Official title
- Impact of an Artificial Intelligence-Based Management Model on Psychological and Behavioral Outcomes in Breast Cancer Patients Undergoing Home CDK4/6 Inhibitor Therapy
- Condition
- CDK4/6 Inhibitors; Depression Anxiety Disorder; Breast Cancer
- Study status
- Enrolling By Invitation
- Sponsor / lead affiliation
- Tianjin Medical University Cancer Institute and Hospital
- Location / country
- China
- Registry
- ClinicalTrials.gov
- External trial ID
- NCT07409298
Why this study may matter
This study may matter because it adds public evidence around anxiety. HopeStage presents it as a starting point for understanding the study, checking the official source, and preparing questions with a care team.
For you
Taking part may give access to a new approach being evaluated.
It requires regular visits and structured follow-up.
Requires travel, with in-person participation in China.
Registry reference
This page links back to the public source record so people can verify details directly with the registry and research team.
If you want the full study description, eligibility criteria, locations, and sponsor information in the original format, this is the place to check before taking the next step.
- Official title
- Impact of an Artificial Intelligence-Based Management Model on Psychological and Behavioral Outcomes in Breast Cancer Patients Undergoing Home CDK4/6 Inhibitor Therapy
- Source
- ClinicalTrials.gov
- Official registry link
- Open official registry
- External trial ID
- NCT07409298
Not medical advice
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
Questions about this study
What is Impact of an Artificial Intelligence-Based Management Model on Psychological and Behavioral Outcomes in Breast Cancer Patients Undergoing Home CDK4/6 Inhibitor Therapy?
This study is exploring behavioral or lifestyle intervention for people with anxiety. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed.
Who is behind this study, and what type of sponsor is it?
This study is sponsored by Tianjin Medical University Cancer Institute and Hospital. Based on the sponsor name or official registry information, it appears to be a university. You should verify the details in the official registry record.
What does participation involve, what phase is it, and what should I ask about safety?
This study may involve behavioral or lifestyle intervention, study visits, and assessments. The time commitment is long follow-up or multiple visits. The study phase is not available in HopeStage data. Check the official source record to see whether a phase is listed. Enrollment is not available in HopeStage data. HopeStage cannot say whether a study is safe or right for you. Before joining, ask the research team about possible risks, time commitment, visits, side effects, compensation, safety monitoring, and whether participation may affect your current care.
Where can I verify the study details?
Use the official source record linked on this page to check the full study description, recruitment status, eligibility criteria, locations, sponsor information, phase, enrollment, contact details, and any listed risks or requirements.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit me